HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026漢康生技全球臨床佈局加速　2026年第一季將於多場國際年會發表口頭及壁報論文

HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

Sustained execution and high-impact data across HanchorBio’s next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1 2026. The selection of multiple abstracts, including four high-profile oral presentations, underscores the clinical maturity and global scientific recognition of HanchorBio’s proprietary pipeline.

The upcoming presentations will feature clinical data from the Company’s lead programs, including the HCB101-101 Phase 1 monotherapy (NCT05892718) and the HCB101-201 Phase 1b/2a combination (NCT06771622) studies, as well as the HCB301-101 Phase 1 monotherapy (NCT06487624) study, highlighting the therapeutic potential of its CD47-SIRPα innate immune backbone and multi-functional biologics:

• HCB101: A highly engineered SIRPα–IgG4 Fc-fusion protein designed to maximize phagocytosis while minimizing hematologic toxicities.
• HCB301: A first-in-class multi-specific candidate targeting the CD47/SIRPα, PD-1/PD-L1, and TGFb pathways to overcome the immunosuppressive tumor microenvironment (TME).

“The concentration of oral and poster presentations at premier global forums like AACR-IO and ESMO-TAT reflects the significant momentum of our clinical programs,” said Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (U.S.A.) of HanchorBio. “By presenting data on both HCB101 and HCB301, we are demonstrating our ability to execute our complex, multi-center trials and our commitment to delivering next-generation innate immune checkpoint therapies to patients globally.”

Q1 2026 Global Scientific Calendar

Following the successful presentation of the high objective response rate with HCB101 combination in second-line gastric cancer from the HCB101-201 Phase 1b/2a combination study at the ASCO Gastrointestinal Cancers Symposium in January, HanchorBio continues its aggressive clinical disclosure schedule with the following upcoming presentations:

About HCB101: A Next-Generation SIRPα Fc-Fusion Protein

HCB101 is a rationally engineered SIRPα–IgG4 Fc fusion protein developed on HanchorBio’s FBDB™ platform to selectively block the CD47–SIRPα innate immune checkpoint while minimizing hematologic toxicity. Unlike earlier anti-CD47 approaches, HCB101 is designed to preserve macrophage-mediated antitumor activity while reducing binding to red blood cells, a limitation that historically constrained the clinical utility of CD47-directed therapies.

HCB101 was engineered using AI-assisted structural modeling to achieve differentiated binding to CD47 on cancer cells while maintaining low affinity for CD47 on red blood cells. Its safety profile, receptor occupancy characteristics, and pharmacologic properties are designed to support integration with established oncology regimens without disrupting standard dosing, safety expectations, or clinical workflows. Across ongoing clinical and translational evaluation, HCB101 has demonstrated consistent target engagement and early antitumor activity as both monotherapy and in combination settings, including tumor types historically considered challenging for CD47-directed therapies.

Together, these attributes position HCB101 as a differentiated innate immune checkpoint backbone with broad potential for a wide variety of combination strategies across solid tumors and hematologic malignancies.

About HCB301: A Tri-Specific Checkpoint Immunotherapy

HCB301 is HanchorBio’s next-generation immunotherapy designed to integrate three synergistic mechanisms into a single molecule: CD47-SIRPα blockade to activate myeloid phagocytosis, PD-1 inhibition to restore exhausted T cells, and TGF-b pathway suppression to counteract immune evasion. Developed using the proprietary FBDB™ platform, HCB301 represents a next-generation approach to multi-checkpoint immunotherapy. Preclinical studies demonstrated enhanced immune activation and potent antitumor activity, and the results were presented at the SITC 2025.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.

漢康生技全球臨床佈局加速　2026年第一季將於多場國際年會發表口頭及壁報論文

憑藉下一代免疫腫瘤產品組合之卓越臨床數據與執行力，漢康生技將於ASCO-GI、AACR-IO、ESMO-TAT、ICHNO 及 WOC 等指標性國際年會亮相。

專注於開發創新癌症與自體免疫疾病免疫療法的全球臨床階段生物技術公司——漢康生技（HanchorBio, Inc.；證券代碼：7827），今日宣布其 2026 年第一季的國際學術參與計畫。憑藉多項研究成果入選重要國際腫瘤學年會，其中包括4場高規格口頭發表（Oral Presentation），彰顯了漢康生技自有研發管線的臨床成熟度，並獲得全球科學界的高度認可。

本次系列發表將展示公司核心產品的臨床進展，涵蓋 HCB101-101 一期單藥研究（NCT05892718）、HCB101-201 一期下半/二期上半（Phase 1b/2a）聯合用藥研究（NCT06771622），以及 HCB301-101 一期單藥研究（NCT06487624）。這些數據將突顯其 CD47-SIRPα先天免疫骨幹及多功能生物藥的治療潛力：

• HCB101：一種高度工程化的 SIRPα-IgG4 Fc 融合蛋白，旨在極大化吞噬作用的同時，降低血液學毒性。
• HCB301：全球首創（First-in-Class）的多特異性候選藥物，同時針對 CD47/SIRPα、PD-1/PD-L1 及 TGFβ 通路，旨在克服抑制性腫瘤微環境（TME）。

漢康集團總裁暨醫療長、以及美國區執行長陸英明（Alvin Luk）博士表示：「能在 AACR-IO 與 ESMO-TAT 等頂尖全球論壇進行多場口頭與壁報發表，反映了漢康臨床計畫的強勁動能。透過分享 HCB101 與 HCB301 的最新臨床數據，我們向世界證明了漢康執行複雜、多中心臨床試驗的能力，以及我們致力於為全球患者提供新一代先天免疫檢查點療法的承諾。」

2026年第一季全球科學年會時程

繼今年一月於美國 ASCO 胃腸道癌症研討會（ASCO-GI）成功發表 HCB101 聯合用藥在二線胃癌治療中表現出高客觀反應率（ORR）後，漢康生技將持續推動積極的臨床數據發布時程：

關於 HCB101: 新一代 SIRPα Fc 融合蛋白

HCB101 是一款經由理性設計的 SIRPα–IgG4 Fc 融合蛋白，基於漢康生技專有的 FBDB™ 平台開發，旨在選擇性阻斷 CD47–SIRPα 先天免疫檢查點，同時將血液學毒性降至最低。不同於早期的抗 CD47 研發路徑，HCB101 的設計旨在保留巨噬細胞介導的抗腫瘤活性，並減少對紅血球的結合；對紅血球的結合過去一直是限制 CD47 標靶療法臨床應用的一大瓶頸。

HCB101 利用 AI 輔助結構建模技術，實現了對癌細胞上 CD47 的差異化結合，同時對紅血球上的 CD47 保持低親和力。其安全性指標、受體佔位特性及藥理屬性，旨在支持其與現有腫瘤治療方案的整合，且不影響標準給藥劑量、安全預期或臨床作業流程。在目前的臨床與轉化研究評估中，HCB101 作為單藥及聯合治療均展現出穩定的標靶結合能力及早期抗腫瘤活性，其涵蓋的腫瘤類型甚至包括過去被認為對 CD47 標靶療法極具挑戰性的癌種。

綜合上述特質，HCB101 已定位為具備差異化的先天免疫檢查點骨幹（Backbone），在實體瘤與血液惡性腫瘤的各類聯合治療策略中展現出廣闊的應用潛力。

關於 HCB301：三特異性免疫檢查點療法

HCB301 是漢康生技的新一代免疫療法，旨在將三種協同機制整合於單一分子中：阻斷 CD47-SIRPα 以激活髓系細胞的吞噬作用、抑制 PD-1 以恢復耗竭的 T 細胞功能，以及抑制 TGF-β 通路以對抗免疫逃逸。HCB301 同樣採用專有的 FBDB™ 平台開發，代表了多重檢查點免疫療法的新一代研發趨勢。臨床前研究已證實其具有增強免疫激活與強效抗腫瘤的能力，相關研究結果先前已於 2025 年癌症免疫治療學會（SITC）年會發表。

關於漢康生技（HanchorBio）

漢康生技（證券代碼：7827.TPEx）總部位於台北、上海及舊金山灣區，是一家專注於免疫腫瘤學及免疫媒介疾病的全球臨床階段生物技術公司。公司由擁有豐富藥物研發與全球臨床開發實戰經驗的資深團隊領軍，致力於重塑癌症治療版圖。

漢康生技致力於重啟人體免疫系統以對抗疾病，其專有的 Fc 基礎設計生物藥（FBDB™）平台能設計出具備多種標靶模式的獨特多功能生物藥，旨在激發先天與後天免疫通路，以克服現有 anti-PD-1/L1 免疫療法的瓶頸。FBDB™ 平台已在多個體內（in vivo）腫瘤動物模型中成功取得概念驗證數據。透過在多功能生物藥研發領域的突破，以及具備高擴展性的 CMC（化學製造與管制）策略，漢康生技正加速推進創新藥物管線，以解決尚未被滿足的重大醫療需求。